Literature DB >> 19203539

Plasma and cellular pharmacokinetics of doxorubicin after intravenous infusion of Caelyx/Doxil in patients with hematological tumors.

H Richly1, M Grubert, M E Scheulen, R A Hilger.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19203539     DOI： 10.5414/cpp47055

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther        ISSN： 0946-1965            Impact factor:   1.366


× No keyword cloud information.
  3 in total

Review 1.  Pegylated liposomal doxorubicin: a review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi's sarcoma.

Authors:  Sean T Duggan; Gillian M Keating
Journal:  Drugs       Date:  2011-12-24       Impact factor: 9.546

2.  Theory and Experimental Validation of a Spatio-temporal Model of Chemotherapy Transport to Enhance Tumor Cell Kill.

Authors:  Zhihui Wang; Romica Kerketta; Yao-Li Chuang; Prashant Dogra; Joseph D Butner; Terisse A Brocato; Armin Day; Rong Xu; Haifa Shen; Eman Simbawa; A S Al-Fhaid; S R Mahmoud; Steven A Curley; Mauro Ferrari; Eugene J Koay; Vittorio Cristini
Journal:  PLoS Comput Biol       Date:  2016-06-10       Impact factor: 4.475

3.  Pharmacokinetics of a liposomal formulation of doxorubicin in rats.

Authors:  Zongyu Liu; Ye Bi; Yating Sun; Fei Hao; Jiahui Lu; Qingfan Meng; Robert J Lee; Yaping Tian; Jing Xie
Journal:  Saudi Pharm J       Date:  2017-05-13       Impact factor: 4.330
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.